-
In Vitro Potency of Xeruborbactam in Combination With Multiple ฮฒ-Lactam Antibiotics in Comparison With Other ฮฒ-Lactam/ฮฒ-Lactamase Inhibitor (BLI) Combinations Against Carbapenem-Resistant and Extended-Spectrum ฮฒ-Lactamase-Producing Enterobacterales
-
New Boronate Drugs and Evolving NDM-Mediated Beta-Lactam Resistance
-
Intrinsic Antibacterial Activity of Xeruborbactam In Vitro: Assessing Spectrum and Mode of Action
-
A Synthetic Lipopeptide Targeting Top-Priority Multidrug-Resistant Gram-Negative Pathogens
-
The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics Against Beta-Lactamase-Producing Strains of Resistant Enterobacterales
-
QPX7728, an Ultra-Broad-Spectrum ฮฒ-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics
-
In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination With Multiple Beta-Lactam Antibiotics Against Pseudomonas Aeruginosa
-
In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination With Meropenem Against Clinical Isolates of Carbapenem-Resistant Acinetobacter Baumannii
-
In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination With Beta-Lactams Against Carbapenem-Resistant Klebsiella Pneumoniae
-
In Vitro Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 Against Carbapenem-Resistant Enterobacterales With Varying Intrinsic and Acquired Resistance Mechanisms